Home > Urology > Oral drug not inferior to intravenous ertapenem for complicated UTI, pyelonephritis

Oral drug not inferior to intravenous ertapenem for complicated UTI, pyelonephritis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
The New England Journal of Medicine
Reuters Health - 06/04/2022 - When treating a complicated urinary tract infection (UTI) or acute pyelonephritis, oral tebipenem pivoxil hydrobromide taken three times daily is not inferior to daily intravenous therapy with ertapenem, according to results of the ADAPT-PO study. The results, published in the New England Journal of Medicine, open the way for a simplified treatment for a condition that affects 3 million people in the United States each year. As antibiotic resistance has grown, so has the need for hospitalization because so many infections involve resistant strains. "In the absence of other effective oral agents, tebipenem pivoxil hydrobromide may provide an option for the treatment of complicated urinary tract infection and acute pyelonephritis due to antibiotic-resistant uropathogens," write Dr. Angela K. Talley of Spero Therapeutics in Cambridge, Massachusetts, and colleagues. The phase-3 double-blind noninferiority trial was done with 868 pati...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on